Table 2.

Comparison between arylstannane chemistry (method A & B, see details in ESI) from the literature and our aryliodonium salts approach for the astatination of the 9E7.4 antibody.

	[211At]SAB RCY (%)d	Conjugation yield (%)e	Overall decay corrected RCY (%)	Procedure duration (min)
Method Aa	33–58f	51–61	20–30	200 ± 10
Method Bb	75–93	27–30	24–29	120 ± 10
This workc	77–84	54–60	53–57	140 ± 10

^aSAB produced from the tin precursor with N-chlorosuccinimide as oxidizing agent and purified by HPLC before conjugation (n = 2).

^bSAB produced from the tin precursor with N-iodosuccinimide as oxidizing agent and conjugated crude without purification (n = 3).

^cSAB produced from aryliodonium 4a and purified on a silica Sep-Pak Vac 3cc (500 mg) cartridge before conjugation (n = 5).

^dDecay corrected RCYs of purified [²¹¹At]SAB.

^eConjugation yields are given after purification by gel filtration. Such purification leads typically to 20–25% loss of radiolabeled antibody on the purification column.

^fCrude RCY was typically 70–90%; major loss due to HPLC purification.